Clinical features and signaling effects of RET D631Y variant multiple endocrine neoplasia type 2 (MEN2)
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background/Aims: Germline mutations of the rearranged during transfection (RET) gene cause multiple endocrine neoplasia type 2 (MEN2). About 85% of RET mutations in MEN2 occur in codon Cys634. The RET D631Y mutation has recently been discovered, and we have studied its molecular expression and clinical consequences. Methods: We analyzed the clinical characteristics of a total of 34 D631Y variant MEN2 individuals from seven families. We also constructed wild-type and mutant C630Y, D631Y, and C634R/W expression vectors and investigated their effects on signaling pathways and ability to correct the phenotypes of RET mutant cells. Results: The median ages at diagnosis of pheochromocytoma and medullary thyroid carcinoma (MTC) were higher in patients with RET D631Y variant MEN2 than in those with the C634R/W variant (49:53.5 years vs. 33.5:27 years, respectively), and the penetration of the D631Y mutation with respect to MTC was lower than that of the C634R/W mutation (32.3% vs. 90%). The effects of the mutant vectors on phosphorylation of RET signaling molecules and focus formation were significantly different from those of wild type, but there were no significant differences between the mutants. D631Y scored significantly higher for chemotaxis and wound healing than C630Y, but lower than C634R and C634W. Conclusions: We suggest that the tumorigenic potential conferred by the D631Y mutation is lower than that conferred by the C634R/W mutation, but higher than that conferred by C630Y. Thus, the risk level of the RET D631Y variant appears to be higher than that of C630Y and lower than that of C634R/W.
Abstract
Background/Aims: Germline mutations of the rearranged during transfection (RET) gene cause multiple endocrine neoplasia type 2 (MEN2). About 85% of RET mutations in MEN2 occur in codon Cys634. The RET D631Y mutation has recently been discovered, and we have studied its molecular expression and clinical consequences. Methods: We analyzed the clinical characteristics of a total of 34 D631Y variant MEN2 individuals from seven families. We also constructed wild-type and mutant C630Y, D631Y, and C634R/W expression vectors and investigated their effects on signaling pathways and ability to correct the phenotypes of RET mutant cells. Results: The median ages at diagnosis of pheochromocytoma and medullary thyroid carcinoma (MTC) were higher in patients with RET D631Y variant MEN2 than in those with the C634R/W variant (49:53.5 years vs. 33.5:27 years, respectively), and the penetration of the D631Y mutation with respect to MTC was lower than that of the C634R/W mutation (32.3% vs. 90%). The effects of the mutant vectors on phosphorylation of RET signaling molecules and focus formation were significantly different from those of wild type, but there were no significant differences between the mutants. D631Y scored significantly higher for chemotaxis and wound healing than C630Y, but lower than C634R and C634W. Conclusions: We suggest that the tumorigenic potential conferred by the D631Y mutation is lower than that conferred by the C634R/W mutation, but higher than that conferred by C630Y. Thus, the risk level of the RET D631Y variant appears to be higher than that of C630Y and lower than that of C634R/W.
참고문헌 (39)
- Melmed S, "Williams Textbook of Endocrinology" (2020), Elsevier
- Wells SA Jr, "Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma", Thyroid, 25, pp.567~610 (2015)
- Brandi ML, "Guidelines for diagnosis and therapy of MEN type 1 and type 2", J Clin Endocrinol Metab, 86, pp.5658~5671 (2001)
- Prazeres H, "How to treat a signal? Current basis for RET-genotype-oriented choice of kinase inhibitors for the treatment of medullary thyroid cancer", J Thyroid Res, 2011, pp.678357~ (2011)
- Waguespack SG, "Management of medullary thyroid carcinoma and MEN2 syndromes in childhood", Nat Rev Endocrinol, 7, pp.596~607 (2011)
- Jameson JL, "Endocrinology: Adult and Pediatric. Vol. 2" (2016), Elsevier Saunders
- Machens A, "Molecular epidemiology of multiple endocrine neoplasia 2 : implications for RET screening in the new millenium", Eur J Endocrinol, 168, pp.307~314 (2013)
- Raue F, "Update multiple endocrine neoplasia type 2", Fam Cancer, 9, pp.449~457 (2010)
- Moline J, "Multiple endocrine neoplasia type 2 : an overview", Genet Med, 13, pp.755~764 (2011)
- de Groot JW, "RET as a diagnostic and therapeutic target in sporadic and hereditary endocrine tumors", Endocr Rev, 27, pp.535~560 (2006)
- Voss RK, "Medullary thyroid carcinoma in MEN2A : ATA moderate-or high-risk RET mutations do not predict disease aggressiveness", J Clin Endocrinol Metab, 102, pp.2807~2813 (2017)
- American Thyroid Association Guidelines Task Force, "Medullary thyroid cancer : management guidelines of the American Thyroid Association", Thyroid, 19, pp.565~612 (2009)
- Berndt I, "A new hot spot for mutations in the ret protooncogene causing familial medullary thyroid carcinoma and multiple endocrine neoplasia type 2A", J Clin Endocrinol Metab, 83, pp.770~774 (1998)
- Elston MS, "Patients with RET D631Y mutations most commonly present with pheochromocytoma and not medullary thyroid carcinoma", Horm Metab Res, 44, pp.339~342 (2012)
- Eng C, "GeneReviews" (1999), University of Washington
- Bae SJ, "A rare extracellular D631Y germline mutation of the RET proto-oncogene in two Korean families with multiple endocrine neoplasia 2A", Thyroid, 16, pp.609~614 (2006)
- Kim JH, "Two cases of RET proto-oncogene mutation in multiple endocrine neoplasia type 2a", Korean J Med, 73, pp.994~1002 (2007)
- Ospina NS, "Clinical features of a family with multiple endocrine neoplasia type 2A caused by the D631Y RET mutation", Thyroid, 27, pp.1332~1334 (2017)
- Asai N, "Mechanism of Ret activation by a mutation at aspartic acid 631 identified in sporadic pheochromocytoma", Biochem Biophys Res Commun, 255, pp.587~590 (1999)
- Asai N, "Mechanism of activation of the ret proto-oncogene by multiple endocrine neoplasia 2A mutations", Mol Cell Biol, 15, pp.1613~1619 (1995)
- Burke W, "Genetic testing", N Engl J Med, 347, pp.1867~1875 (2002)
- Lips CJ, "Clinical management of the multiple endocrine neoplasia syndromes : results of a computerized opinion poll at the Sixth International Workshop on Multiple Endocrine Neoplasia and von Hippel-Lindau disease", J Intern Med, 243, pp.589~594 (1998)
- Machens A, "Familial prevalence and age of RET germline mutations: implications for screening", Clin Endocrinol (Oxf), 69, pp.81~87 (2008)
- Mathiesen JS, "Distribution of RET mutations in multiple endocrine neoplasia 2 in Denmark 1994-2014 : a nationwide study", Thyroid, 27, pp.215~223 (2017)
- Aldemir O, "A family diagnosed as MEN2A with a rare mutation D631Y in RET oncogene", West Indian Med J (2016)[DOI]
- Yonekawa H, "A family of multiple endocrine neoplasia type 2A(MEN 2A)with Cys630Tyr RET germline mutation : report of a case", Endocr J, 54, pp.531~535 (2007)
- Quayle FJ, "Pheochromocytoma penetrance varies by RET mutation in MEN 2A", Surgery, 142, pp.800~805 (2007)
- Zhou Y, "RET proto-oncogene mutations are restricted to codons 634 and 918 in mainland Chinese families with MEN2A and MEN2B", Clin Endocrinol(Oxf), 67, pp.570~576 (2007)
- Jindrichova S, "Screening of six risk exons of the RET proto-oncogene in families with medullary thyroid carcinoma in the Czech Republic", J Endocrinol, 183, pp.257~265 (2004)
- Chung YJ, "RET proto-oncogene mutations are restricted to codon 634 and 618 in Korean families with multiple endocrine neoplasia 2A", Thyroid, 14, pp.813~818 (2004)
- Punales MK, "RET codon 634mutations in multiple endocrine neoplasia type 2 : variable clinical features and clinical outcome", J Clin Endocrinol Metab, 88, pp.2644~2649 (2003)
- Milos IN, "Age-related neoplastic risk profiles and penetrance estimations in multiple endocrine neoplasia type 2A caused by germ line RET Cys634Trp(TGC>TGG)mutation", Endocr Relat Cancer, 15, pp.1035~1041 (2008)
- Qi XP, "Spectrum of germline RET variants identified by targeted sequencing and associated multiple endocrine neoplasia type 2 susceptibility in China", BMC Cancer, 21, pp.369~ (2021)
- Machens A, "Early malignant progression of hereditary medullary thyroid cancer", N Engl J Med, 350, pp.943~ (2004)
- Lang BH, "Bilateral pheochromocytomas in MEN2A syndrome : a two-institution experience", World J Surg, 39, pp.2484~2491 (2015)
- Colombo C, "The modifier role of RET-G691S polymorphism in hereditary medullary thyroid carcinoma : functional characterization and expression", penetrance studies, 2015, pp.10, 25~
- Newey PJ, "Multiple endocrine neoplasia", Endocr Cancer, 45, pp.538~542 (2017)
- DeNardo BD, "Quantitative phosphoproteomic analysis identifies activation of the RET and IGF-1R", IR signaling pathways in neuroblastoma, 2013, pp.8, e82513~
- Phay JE, "Targeting RET receptor tyrosine kinase activation in cancer", Clin Cancer Res, 16, pp.5936~5941 (2010)